EU Medtech Reform Proposals May Jeopardize Authorized Representatives; Exacerbate 'Ghost' Problem
This article was originally published in SRA
Executive Summary
A new clause in the draft EU regulations for medical devices and IVDs - to make authorized representatives fully liable for defective devices in cases where the product manufacturer is not established in any EU member state - could have a devastating effect on how independent authorized representatives operate and force many of them to shut shop, warns the European Association of Authorised Representatives.
You may also be interested in...
Global Pharma Guidance Tracker – March 2024
Stay up to date on regulatory guidelines from around the world with the Pink Sheet's Guidance Tracker. The complete Global Pharma Guidance Tracker, with sortable and searchable listings going back to 2014, is available online.
EU Regulators Explain How To Ensure Transitioned Trials Align With CTR
Members of the EU’s Clinical Trials Coordination Group have developed harmonized requirements for updating trials that are transitioned to the Clinical Trials Information System based on a minimum set of documents.
Global Medtech Guidance Tracker: March 2024
Stay current on regulatory guidelines from around the world with Medtech Insight's Guidance Tracker. Fifty-nine documents have been posted on the tracker since its last update.